Immunology / Virology & Vaccines

#Covid-19 #Immunology / Virology & Vaccines #Patent Law

DDW Editor exclusive comment on pharma’s Covid IP crisis

DDW Editor Reece Armstrong takes a look at the recent Covid-19 patent battles involving key players in the pharmaceutical sector.  There’s no doubting that when the time came for the life sciences industry to step up during the Covid-19 pandemic, it delivered. From diagnostics to PPE and eventually the launch of Covid-19… Read More

#Exclusive Content

#Clinical trials #Immunology / Virology & Vaccines #Malaria #US

Positive results for US Malaria vaccine, trial shows 

A monoclonal antibody (mAb) treatment for the prevention of Malaria has shown encouraging results in a US Phase I clinical trial.   The mAb, known as L9LS, was developed by scientists at the National Institutes of Health’s (NIH) Vaccine Research Centre (VRC). L9LS is a laboratory-made version of… Read More

#News

#Alzheimer's #Business #Immunology / Virology & Vaccines #Oncology

This week in drug discovery (8-12 August)  

News round-up by DDW’s Reece Armstrong for 8-12 August  New insights into melanoma, a company transition into life sciences and a Lyme disease vaccine are some of the stories in this week’s news round-up. Pfizer launches Phase III trial for Lyme disease vaccine    Pfizer… Read More

#News

#Drug development #Immunology / Virology & Vaccines #Lyme Disease #Pfizer

Pfizer launches Phase III trial for Lyme disease vaccine  

Pfizer has launched a Phase III clinical trial of a vaccine to protect people against Lyme disease, in collaboration with pharmaceutical company Valneva.   The Vaccine Against Lyme for Outdoor Recreationists (VALOR) trial will investigate the efficacy, safety and immunogenicity of Pfizer and Valneva’s Lyme disease vaccine… Read More

#News

#Clinical trial #Immunology / Virology & Vaccines #Rabies

Promising first clinical trial data for new rabies vaccine candidate

Researchers from the University of Oxford have today reported new findings from a Phase I clinical trial studying the immune response and safety of their newly-developed single shot rabies vaccine, ChAdOx2 RabG. The RAB001 trial was conducted at the University and is the first time the novel rabies vaccine has… Read More

#News

#Covid-19 #Immunology #Immunology / Virology & Vaccines

Promising developments in pursuit to design pan-coronavirus vaccine

Researchers at the Francis Crick Institute in the UK, have shown that a specific area of the SARS-CoV-2 spike protein is a promising target for a pan-coronavirus vaccine that could offer some protection against new virus variants, common colds, and help prepare for future pandemics. Developing a vaccine that provides… Read More

#Editor's Choice #News #Trending News

#BioNTech #Covid-19 #Immunology / Virology & Vaccines #mRNA

BioNTech to deliver prestigious lecture on mRNA  

Pharmaceutical company BioNTech will deliver the 2022 César Milstein Lecture on 26 July with a focus on how messenger RNA (mRNA) technology can be used within vaccines for cancer and Covid-19.   The lecture will be delivered in two halves by Uğur Şahin and Özlem Türeci, co-founders of… Read More

#News

#Covid-19 #Immunology / Virology & Vaccines #Infectious diseases #WHO

WHO updates Covid-19 strategy to reach unvaccinated  

The World Health Organisation (WHO) has released an update to its ongoing global Covid-19 strategy in order to reach individuals yet to be vaccinated.   The update to WHO’s Global Covid-19 Vaccination Strategy1, was made in response to the spread of Omicron subvariants, advances in vaccine evidence, and… Read More

#News

#Immunology / Virology & Vaccines #Infectious diseases #Monkeypox

SIGA’s monkeypox treatment gets UK approval  

Pharmaceutical company SIGA Technologies has announced that its oral therapy tecovirimat has been approved in the UK for the treatment of smallpox, monkeypox, cowpox.  The therapy has also been approved for the treatment of complications following vaccination against smallpox in adults and children with a body weight… Read More

#News

Audience
#BioLago #Covid-19 #Immunology / Virology & Vaccines

BioLago’s ‘Science meets business’ event makes successful return 

After a two-year break, the cross-border health network BioLago’s in-person forum returned: ‘Science meets business’ took place 8 July 2022 at the University of Konstanz, Germany.   Around 70 people attended the afternoon forum and networking event, with visitors ranging from technology and service providers, academics, researchers, and… Read More

#News

#GSK #Immunology / Virology & Vaccines #Sustainability

GSK’s annual Palio meeting focuses on sustainability

GSK’s annual Palio meeting is taking place with a focus on how preventative approaches to disease can help mitigate climate change.  GSK’s ‘Vaccines for a sustainable planet’ meeting is gathering 65 experts across immunology, vaccinology, epidemiology, and policy throughout 7-8 July.  The meeting will include… Read More

#News

#Antimicrobial resistance (AMR) #Covid-19 #Immunology / Virology & Vaccines

This week in drug discovery (July 4-8)

A Covid-19 lawsuit, a heart attack treatment developed using spider venom and a collaboration to fight antimicrobial resistance (AMR) are some of the theme’s of this week’s news round-up.  News round-up by DDW’s Reece Armstrong for 4 – 8 July. CureVac lawsuit against BioNTech over Covid-19 vaccine technology Biopharmaceutical… Read More

#News

#Assay #Immunology / Virology & Vaccines #Monkeypox

Novacyt launches monkeypox assay in response to outbreak  

Clinical diagnostics company Novacyt has launched a polymerase chain reaction (PCR) monkeypox assay in response to the recent outbreak of the virus non-endemic countries.   The company’s monkeypox assay is for research-use only (RUO) and has been developed in two forms for the detection of the virus genome in… Read More

#News

#GSK #Immunology / Virology & Vaccines #Measles

US gets another MMR vaccine option in GSK’s Priorix  

GSK’s vaccine for the prevention of measles, mumps and rubella (MMR) has been approved by the US FDA, the company has announced.  The approval of GSK’s Priorix in the US gives patients another option for being vaccinated against MMR. The vaccine is already licensed in over… Read More

#News

Mosquito
#Clinical trial #Immunology / Virology & Vaccines #NIAID

Early positive results for mosquito-borne virus vaccine  

A vaccine for a range of mosquito-borne viruses has received positive results from a Phase I clinical trial.  Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC) have developed a vaccine for eastern equine encephalitis virus (EEEV), western equine encephalitis virus… Read More

#News

#Covid-19 #HIV #Immunology / Virology & Vaccines

ReiThera and Exothera collaborate to develop vaccines for Africa

Biotech company ReiThera is collaborating with contract development and manufacturing organisation (CDMO) Exothera on a project to develop Covid-19 and HIV vaccines for low-and middle-income countries (LMIC). The collaboration will see the companies develop and deliver new low-cost vaccines based on ReiThera’s GRAd technology platform for LMICs in Africa. Exothera… Read More

#News